The Medical Letter on Drugs and Therapeutics
Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Metreleptin (Myalept – Amylin), a recombinant leptin analog produced in E. coli, has been approved by the FDA to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It has not been approved to date for the treatment of partial lipodystrophies, including those associated with the use of protease inhibitors in patients with HIV. Metreleptin is approved in Japan for the treatment of any lipodystrophy disorder.

THE DISORDER — Generalized lipodystrophy is a rare disorder with fewer than 500 known cases in the world.1 Congenital and acquired generalized lipodystrophy are characterized by a near total lack of adipose tissue. Fat is deposited ectopically in muscle and liver tissue and can cause metabolic complications including insulin resistance, hyperinsulinemia, diabetes mellitus, and non-alcoholic fatty ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
Article code: 1460b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian